This segment focuses on the research, development, and commercialization of therapeutics for men's health conditions, primarily erectile dysfunction (ED) and Peyronie's disease. Research and development activities include the development of Stendra (avanafil), an oral PDE5 inhibitor, and H100, a topical formulation for Peyronie's disease. The company utilizes small molecule drug technology and is exploring mechanisms for Rx-to-OTC switch for Stendra. Patient impact is focused on improving the quality of life for men suffering from ED and Peyronie's disease. Market positioning is centered on providing innovative solutions in the self-care market. Future opportunities include expanding the product portfolio and exploring new therapeutic areas within men's health. Regulatory and clinical aspects involve obtaining FDA approvals and conducting clinical trials to demonstrate safety and efficacy. Partnerships with market-leading big data providers and software developers are key to enhancing the company's AI platform and expanding market reach.

This segment encompasses the sales, marketing, and distribution of Petros Pharmaceuticals' products, including Stendra. The company has a full range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The focus is on expanding access to Stendra and driving sales growth through strategic partnerships, such as the exclusive marketing agreement with Hims & Hers Health, Inc. The segment leverages digital health platforms and AI-integrated tools to enhance customer engagement and improve patient outcomes. Market positioning is strengthened through partnerships with market-leading big data providers and software developers. Future opportunities include expanding the product portfolio and exploring new therapeutic areas within men's health. Regulatory and clinical aspects involve obtaining FDA approvals and conducting clinical trials to demonstrate safety and efficacy.